J Am Pharm Assoc (2003). 2019 May-Jun;59(3):398-402. doi: 10.1016/j.japh.2019.01.018. Epub 2019 Mar 8.
To increase access to hepatitis C virus (HCV) care and cure by deploying clinical pharmacy specialist (CPS) providers across the largest integrated health care system in the United States.
National integrated health care system.
In late 2016, the Department of Veterans Affairs (VA) Pharmacy Benefits Management Clinical Pharmacy Practice Office (CPPO) partnered with the VA HIV, Hepatitis, and Related Conditions Program with the central priority of expanding veteran access to novel HCV treatments and timely cure to ultimately prevent morbidity and mortality associated with HCV disease progression. This successful collaboration resulted in clinical resource funding to bolster access to HCV treatment through the deployment of CPS providers. This enterprise-wide initiative to expand clinical pharmacy services for unmet health care needs in HCV treatment resulted in 52 VA facilities submitting full-time employment equivalent (FTEE) funding requests totaling more than $10 million dollars. Facilities may have requested funding for 1 or more FTEEs.
Facilities hired 47 CPS providers and 5 clinical pharmacy technicians. CPS providers in this project recorded 24,888 patient care encounters providing care for 9593 unique patients and initiated new HCV treatment for 1191 treatment-naïve patients. For an additional 8402 patients, the CPS provided HCV care activities such as evaluation and monitoring before, during, and after treatment. CPPO estimates that the same care delivered by nonpharmacist provider specialists (e.g., specialty physicians) cost an additional $936,535, or 48% more.
The deployment of HCV CPS resulted in a significant number of new HCV patients being screened and treated within the VA system.
通过在美国最大的综合医疗保健系统中部署临床药剂师专家 (CPS) 提供者，增加获得丙型肝炎病毒 (HCV) 护理和治疗的机会。
全国性综合医疗保健系统。
2016 年末，美国退伍军人事务部 (VA) 药品福利管理临床药剂师实践办公室 (CPPO) 与 VA HIV、肝炎和相关疾病项目合作，其核心重点是扩大退伍军人获得新型 HCV 治疗方法的机会，并及时治愈，最终预防与 HCV 疾病进展相关的发病率和死亡率。这种成功的合作导致了临床资源的资助，通过部署 CPS 提供者来加强 HCV 治疗的机会。这项扩大临床药学服务以满足 HCV 治疗中未满足的医疗需求的全企业倡议导致 52 个 VA 设施提交了总计超过 1000 万美元的全职等效 (FTEE) 资金申请。各设施可能已为 1 个或多个 FTEE 申请了资金。
各设施聘请了 47 名 CPS 提供者和 5 名临床药剂师技术员。该项目中的 CPS 提供者记录了 24888 次患者护理接触，为 9593 名独特的患者提供了护理，并为 1191 名未经治疗的患者开始了新的 HCV 治疗。对于另外 8402 名患者，CPS 提供了 HCV 护理活动，如治疗前、治疗中和治疗后的评估和监测。CPPO 估计，由非药剂师提供者专家（例如，专业医生）提供的相同护理将额外增加 936535 美元，即增加 48%。
部署 HCV CPS 导致 VA 系统内有大量新的 HCV 患者接受筛查和治疗。
